Sign in Subscribe
Type 2 diabetes

Dexmedetomidine's Impact on Glucose Regulation in Diabetic Patients Undergoing Colon Cancer Surgery

Strategic Insights

— 2 min read

Researchers from the First Affiliated Hospital of Chongqing Medical University conducted a randomized double-blinded controlled trial to investigate the effect of dexmedetomidine on glucose homeostasis in patients with type 2 diabetes undergoing laparoscopic colorectal cancer radical resection. The study involved 80 participants with type 2 diabetes, who were divided into four groups: control group (group C), dexmedetomidine 1 mg kg-1 + 0.25 mg kg-1 h-1 (group D1), 1 mg kg-1 + 0.5 mg kg-1 h-1 (group D2), and 1 mg kg-1 + 0.75 mg kg-1 h-1 (group D3). The levels of blood glucose were measured at different time points during the surgery and in the post-anesthetic care unit (PACU).

Key Takeaways:

  • Dexmedetomidine has a significant impact on glucose homeostasis in patients with type 2 diabetes undergoing laparoscopic colorectal cancer radical resection.
  • A loading dose of 1 mg/kg and a maintenance dose of 0.25 mg/kg/h can be used in type 2 diabetic patients for better glucose regulation without increasing the incidence of perioperative hyperglycemia.
  • The study found that dexmedetomidine can prevent an increase in blood glucose levels in patients with type 2 diabetes undergoing surgery.
  • The results suggest that dexmedetomidine can be an effective tool for managing glucose levels in patients with type 2 diabetes during surgery.
  • The study was registered on January 13, 2021, with ChiCTR (ChiCTR2100042050).
  • The researchers found that dexmedetomidine had a positive effect on glucose regulation in type 2 diabetic patients, reducing the incidence of perioperative hyperglycemia and adverse effects.

Statistics:

  • 80 participants with type 2 diabetes were involved in the study.
  • The study involved four groups: control group (group C), dexmedetomidine 1 mg kg-1 + 0.25 mg kg-1 h-1 (group D1), 1 mg kg-1 + 0.5 mg kg-1 h-1 (group D2), and 1 mg kg-1 + 0.75 mg kg-1 h-1 (group D3).
  • The levels of blood glucose were measured at five different time points: before the intravenous infusion of dexmedetomidine (T1), 15 min after the intubation (T2), 1 h after the beginning of the surgery (T3), at the end of the surgery (T4), and 30 min after the extubation in PACU (T5).
  • The study found that dexmedetomidine prevented an increase in blood glucose levels in patients with type 2 diabetes undergoing surgery.

Sources:

  • First Affiliated Hospital of Chongqing Medical University
  • Trials (journal)
  • BMC (publisher)
  • https://trialsjournal.biomedcentral.com
  • https://doi-org.sdpl.idm.oclc.org/10.1186/s13063-025-09094-0
  • Wei Dai, Department of Anesthesiology, First Affiliated Hospital of Chongqing Medical University
  • Jinlong Zhou, Lunjing Qu, Kaihua He
  • ChiCTR2100042050 (trial registration)
  • Cancer Weekly (news publication)

Read more